Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?
Open Access
- 20 March 2006
- journal article
- review article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 60 (4), 450-456
- https://doi.org/10.1111/j.1368-5031.2006.00858.x
Abstract
Risk factors for invasive pneumococcal disease (IPD) include young and old age, comorbidities (such as splenic dysfunction, immunodeficiencies, chronic renal disease, chronic heart or lung disease or cerebral spinal fluid leak), crowded environments or poor socioeconomic conditions. Universal use of the 7-valent pneumococcal conjugate (7vPncCRM) vaccine for infants and young children has led to significant decreases in IPD in the vaccinated population (direct protection), and there has also been a decrease in the incidence of IPD among the nonvaccinated population (indirect immunity; herd protection). While 7vPncCRM vaccine is administered universally to children in USA, many countries of the European Union have chosen to target children with comorbidities. This review aims to highlight individual risk factors for IPD, describe studies that evaluated pneumococcal conjugate vaccines in at-risk groups and estimate the proportion of at-risk children who may have been vaccinated in the European Union since the 7vPncCRM vaccine was introduced, using UK as an example. Although immunisation targeting only children with comorbidities may achieve satisfactory results for a few, many otherwise healthy children at risk simply because of their age will be neglected, and herd protection might not be established.Keywords
This publication has 31 references indexed in Scilit:
- Pneumococcal bacteremia in children: an 8-year review in two hospitals in BarcelonaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisationArchives of Disease in Childhood, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionThe New England Journal of Medicine, 2003
- Increased Protection against Pneumococcal Disease by Mucosal Administration of Conjugate Vaccine plus Interleukin-12Infection and Immunity, 2003
- Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantationBlood, 2003
- Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998The Pediatric Infectious Disease Journal, 2002
- Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 Among Infants With Sickle Cell DiseasePEDIATRICS, 2000
- Risk Factors for Invasive Pneumococcal Disease in Children: A Population-based Case–Control Study in North AmericaPediatrics, 1999
- Estimating the transmission parameters of pneumococcal carriage in householdsEpidemiology and Infection, 1999
- Safety and Immunogenicity of Three Doses of a Five-Valent Pneumococcal Conjugate Vaccine in Children Younger Than Two Years With and Without Human Immunodeficiency Virus InfectionPEDIATRICS, 1997